Across TCGA pan-cancer cohorts, TTC30A Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TTC30A data layer compared with 29 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher TTC30A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TTC30A expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LUSC, UCEC, and BLCA are the cancer types where TTC30A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	II,III,IV	0.427	0.745	.008	36	view →
UCEC	DFS	Median	All	0.968	0.615	.005	32	view →
BLCA	OS	Median	All	0.212	0.620	.007	18	view →
LIHC	OS	Median	All	0.118	0.783	<.001	12	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: TTC30A tumor-vs-normal RNA expression · all TTC30A data types